Evidence map›Paper›PMID 34711017›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2021

Anti-Proliferative and Pro-Apoptotic Activities of Synthesized 3,4,5 Tri-Methoxy Ciprofloxacin Chalcone Hybrid, through p53 Up-Regulation in HepG2 and MCF7 Cell Lines.

Marwa A Eisa, Moustafa Fathy, Gamal El-Din A A Abuo-Rahma, Mohamed Abdel-Aziz, Maiiada Hassan Nazmy

Abstract read
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. A New EGFR Inhibitor fromCurrent issues in molecular biology · 2022
    Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Marwa A EisaBiochemistry Department, Faculty of Pharmacy, Minia University, Minia 61519, Egypt.
Moustafa FathyBiochemistry Department, Faculty of Pharmacy, Minia University, Minia 61519, Egypt.
Gamal El-Din A A Abuo-RahmaMedicinal Chemistry Department, Faculty of Pharmacy, Minia University, Minia 61519, Egypt.
Mohamed Abdel-AzizMedicinal Chemistry Department, Faculty of Pharmacy, Minia University, Minia 61519, Egypt.
Maiiada Hassan NazmyBiochemistry Department, Faculty of Pharmacy, Minia University, Minia 61519, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCancer is a significant health problem around the world and one of the leading causes of human death. The need for novel, selective and non-toxic anti-cancer agents is still urging. AIM OF THE WORK: to investigate the anti-proliferative and pro-apoptotic effects of the synthesized ciprofloxacin 3,4,5 tri-methoxy chalcone hybrid (CCH) on the HepG2 hepatocellular carcinoma and MCF7 breast carcinoma cell lines. MATERIALS AND

methodsHepG2 and MCF7cell lines were treated with CCH. Cell viability and cell cycle analysis were performed. Protein and mRNA expression levels of P53, COX-2 and TNF-α were analyzed by western blotting and RT-PCR respectively.

resultsCCH caused concentration and time-dependent reduction in the viability of human HepG2 and MCF7 cells, pre-G1 apoptosis and cell cycle arrest at G2/M stage, significantly higher P53 and TNF-α mRNA and protein expression levels but significantly lower COX2 mRNA and protein expression levels.

conclusionCCH showed obvious anti-proliferative and apoptosis-inducing activities in both cell lines.

Indexed as

ApoptosisCell ProliferationCell SurvivalChalconesCiprofloxacinCyclooxygenase 2Drug CombinationsG2 Phase Cell Cycle CheckpointsHep G2 CellsHumansMCF-7 CellsM Phase Cell Cycle CheckpointsRNA, MessengerTumor Necrosis Factor-alphaTumor Suppressor Protein p53ChalconesCiprofloxacinCyclooxygenase 2Drug CombinationsRNA, MessengerTumor Necrosis Factor-alphaTumor Suppressor Protein p53ApoptosisCiprofloxacinCOX-2p53

Identifiers

PMID34711017
PMCPMC8858240

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.